Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?

Company Overview - Accuray (ARAY) shares have increased by approximately 17% over the past month, outperforming the S&P 500 [1] - The most recent earnings report is crucial for understanding the stock's performance and future outlook [1] Earnings Estimates - Estimates for Accuray have trended downward in the past month, with a consensus estimate shift of -60% [2] - The downward revisions indicate a negative outlook for the stock [4] VGM Scores - Accuray has a strong Growth Score of A, but a lower Momentum Score of C [3] - The stock received a B grade for value, placing it in the top 40% of this investment strategy [3] - The aggregate VGM Score for Accuray is A, which is significant for investors not focused on a single strategy [3] Industry Performance - Accuray is part of the Zacks Medical - Instruments industry, where Edwards Lifesciences (EW) has seen a 3.4% gain over the past month [5] - Edwards Lifesciences reported revenues of $1.41 billion for the last quarter, reflecting a year-over-year decline of -11.6$0.62, indicating a year-over-year change of -11.4% [6] - Edwards Lifesciences also holds a Zacks Rank 3 (Hold) based on estimate revisions [6]